Kim Bure

Hudson Institute — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

10h-index319citations20works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Pluripotent Stem Cells Research(9), Biomedical Ethics and Regulation(9), 3D Printing in Biomedical Research(8), CRISPR and Genetic Engineering(3), Viral Infectious Diseases and Gene Expression in Insects(3)

Publications20 total

Biotechnology and Bioengineering: Volume 116, Number 2, February 2019
Biotechnology and Bioengineering·2019Open Access
Bioprocess decision support tool for scalable manufacture of extracellular vesicles
Biotechnology and Bioengineering·2018· 38 citedOpen Access
Bioprocessing automation in cell therapy manufacturing: Outcomes of special interest group automation workshop
Cytotherapy·2018· 15 cited
An assessment of the factors affecting the commercialization of cell-based therapeutics: a systematic review protocol
Systematic Reviews·2017· 10 citedOpen Access
A quantitative, multi-national and multi-stakeholder assessment of barriers to the adoption of cell therapies
Journal of Tissue Engineering·2017· 15 citedOpen Access
An assessment of the factors affecting the commercialization of cell-based therapeutics: a systematic review protocol
DSpace@MIT (Massachusetts Institute of Technology)·2017Open Access
Corrigendum: A Quantitative Assessment of Factors Affecting the Technological Development and Adoption of Companion Diagnostics
Frontiers in Genetics·2016Open Access
Challenges and Opportunities in the Development of Induced Pluripotent Stem Cell Therapeutics
BENTHAM SCIENCE PUBLISHERS eBooks·2016
A Quantitative Assessment of Factors Affecting the Technological Development and Adoption of Companion Diagnostics
Frontiers in Genetics·2016· 12 citedOpen Access
Open Access Could Transform Drug Discovery: A Case Study of JQ1
Expert Opinion on Drug Discovery·2016· 38 citedOpen Access
Enabling Consistency in Pluripotent Stem Cell-Derived Products for Research and Development and Clinical Applications Through Material Standards
Stem Cells Translational Medicine·2015· 35 citedOpen Access
Generating iPSCs: Translating Cell Reprogramming Science into Scalable and Robust Biomanufacturing Strategies
Cell stem cell·2015· 63 citedOpen Access
Global strategic partnerships in regenerative medicine
Trends in biotechnology·2014· 9 cited
The global intellectual property landscape of induced pluripotent stem cell technologies
Nature Biotechnology·2014· 40 cited
Novel platform technology for scale down and process optimisation for regenerative medicine
Cytotherapy·2014· 2 cited
CASMI TSCC Launch Event, Paris, France, July 2013: An Assessment of the Key Barriers to the Commercialization and Clinical Adoption of Pluripotent Stem Cell Therapies
Rejuvenation Research·2014· 3 citedOpen Access
Cell therapy bioprocessing technologies and indicators of technological convergence
UCL Discovery (University College London)·2014· 7 cited
Quantitative assessment of barriers to the clinical development and adoption of cellular therapies: A pilot study
Journal of Tissue Engineering·2014· 26 citedOpen Access
The Implementation of Novel Collaborative Structures for the Identification and Resolution of Barriers to Pluripotent Stem Cell Translation
Stem Cells and Development·2013· 6 citedOpen Access
Overcoming scale-up and scale-out with automation
Cytotherapy·2013

Frequent Co-authors

David Brindley(17), Anna French(12), Brock Reeve(12), James Smith(10), Benjamin M. Davies(9), Richard Barker(7), Jeffrey M. Karp(7), David Williams(6), Ivan Wall(6), Evan Y. Snyder(4), Mackenna Roberts(4), Sue Dopson(4), David DiGiusto(4), Hannah Hurley(3), Andrew Carr(3), Kelvin S. Ng(3), Ben Mead(3), Zeeshaan Arshad(3), Georg A. Holländer(3), Sarah Rikabi(3)